Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

被引:0
作者
Jin Zhang
Hongchuan Jiang
Jian Zhang
Guoqiang Bao
Guoqiang Zhang
Haibo Wang
Xi Wang
机构
[1] Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Clinical Research Center for Cancer,Third Department of Breast Surgery
[2] Capital Medical University,Department of Breast Surgery, Beijing Chaoyang Hospital
[3] Fudan University Shanghai Cancer Center,Department of Medical Oncology
[4] The Fourth Military Medical University,General Surgery Department, Tangdu Hospital
[5] Harbin Medical University Cancer Hospital,Department of Breast Surgery
[6] The Affiliated Hospital of Qingdao University,Department of Breast Surgery
[7] Sun Yat-sen University Cancer Center,Department of Breast Surgery
来源
BMC Cancer | / 21卷
关键词
Adjuvant chemotherapy; Breast cancer; Epirubicin; Neoadjuvant chemotherapy; Pegylated liposomal doxorubicin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 198 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2018)Current status of neoadjuvant endocrine therapy in early stage breast Cancer Curr Treat Options in Oncol 19 23-395
[3]  
Soerjomataram I(1987)Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base Am J Clin Oncol 10 387-827
[4]  
Siegel RL(2009)Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk Ann Oncol 20 816-1988
[5]  
Torre LA(2015)Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy Circulation 131 1981-42
[6]  
Jemal A(2020)Cardiotoxicity of anthracyclines Front Cardiovasc Med 7 26-361
[7]  
Reinert T(2016)Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging Circ Heart Fail 9 e002661-449
[8]  
Gonçalves R(2017)2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur J Heart Fail 19 9-274
[9]  
Ellis MJ(2016)Curing cancer, saving the heart: a challenge that cardioncology should not miss Curr Cardiol Rep 18 51-1788
[10]  
Jones SE(1995)Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients Med Pediatr Oncol 24 352-2223